On April 24, 2024, Dr. Martin Faulkes and Dr. Edward Futcher each informed the Board of Directors of VolitionRx Limited of their intention to retire from the Board of the Company following the conclusion of the current director service year and to not stand for re-election at the Company?s 2024 Annual Meeting of Stockholders (the ?Annual Meeting?), which is expected to be held on July 2, 2024. Dr. Faulkes will also step down as Executive Chairman, and Dr. Futcher will also step down as a member and Chair of the Board?s Nominations and Governance Committee and member of the Audit Committee, at the same time. Following the Annual Meeting, and pursuant to his employment agreement, Dr. Faulkes will continue to be employed by the Company for a three-month period to assist with the transition of the Chairman position among other duties.

Dr. Faulkes served on the Board for more than 12 years and Dr. Futcher served on the Board for more than 7 years. As such, the Board has determined to reduce the size of the Board from eight to six directors, effective immediately prior to the Annual Meeting. The Board expects to nominate six directors to stand for re-election at the Annual Meeting.

Assuming the re-election of the Board-nominated director nominees at the Annual Meeting, the Board has appointed Guy Innes as interim Chairman of the Board and as the Chair of the Nominations and Governance Committee, effective immediately upon such re-election, in addition to his continuing role as a member and Chair of the Audit Committee. Each of Drs. Faulkes?

and Futcher?s decision to step down from the Board is not the result of any dispute or disagreement with the Company or its Board.